

CLAIMS

We Claim

1. A polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77) and human V2 (SEQ ID NO: 78).
2. A pharmaceutical composition for the treatment of an inflammatory neurological disorder comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), and human V2 (SEQ ID NO: 78).
3. A pharmaceutical composition according to claim 2 wherein the inflammatory neurological disorder is multiple sclerosis.
4. A pharmaceutical composition according to claim 2 wherein the inflammatory neurological disorder is Parkinson's disease.
5. A pharmaceutical composition for the treatment of diabetes mellitus comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), and human V2 (SEQ ID NO: 78).
6. A pharmaceutical composition according to claim 2 wherein the inflammatory

neurological disorder is Alzheimer's disease.

- SUB
A31
7. An antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78), murine V3 (SEQ ID NO: 79) and human V3 (SEQ ID NO: 80).
8. An antibody according to claim 7 wherein the antibody is a human monoclonal antibody.
9. An antibody according to claim 7 wherein the antibody is an Fab fragment of an antibody.
10. A vaccine composition for the treatment of an inflammatory neurological disorder comprising an antigen for the antibody of claim 7.
11. A vaccine composition according to claim 10 wherein the inflammatory neurological disorder is multiple sclerosis.
12. A vaccine composition according to claim 11 wherein the inflammatory neurological disorder is Parkinson's disease.
13. A vaccine composition according to claim 12 wherein the inflammatory neurological disorder is Alzheimer's disease.
14. A vaccine composition for the treatment of diabetes mellitus comprising an antigen for the antibody of claim 7.
- SUB
A32
15. A method for treating an inflammatory neurological disorder comprising the step of

SUB
A32

administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) human V3 (SEQ ID NO: 79) and (b) an antibody to the polypeptide of (a).

16. A method according to claim 15 wherein a dose of 0.001mg/kg to 50mg/kg is administered to the patient.

17. A method according to claim 15 wherein the inflammatory neurological disorder is selected from the group consisting of multiple sclerosis, Parkinson's disease and Alzheimer's disease.

18. A method according to claim 15 wherein the dose is administered according to a regime selected from the group consisting of a single dose, multiple daily doses, multiple weekly doses and multiple monthly doses.

SUB
A33

19. A method for treating a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus, the method comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) and (b) an antibody to the polypeptide of (a).

20. A method according to claim 19 wherein a dose of 0.001mg/kg to 50mg/kg is administered to the patient.

21. A method according to claim 19 wherein the inflammatory neurological disorder is selected from the group consisting of multiple sclerosis, Parkinson's disease and Alzheimer's disease.

22. A method according to claim 19 wherein the dose is administered according to a regime selected from the group consisting of a single dose, multiple daily doses, multiple weekly doses and multiple monthly doses.

23. A method for treating wounds comprising the step of administering to a patient a compound selected from the group consisting of (a) a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) and (b) an antibody to the polypeptide of (a).

24. Use of polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) for the treatment of an inflammatory neurological disorder.

25. Use of the polypeptide of claim 24 wherein the inflammatory neurological disorder is multiple sclerosis.

26. Use according to claim 24 wherein the inflammatory neurological disorder is Parkinson's disease.

27. Use according to claim 24 wherein the inflammatory neurological disorder is Alzheimer's disease.

SUB
A35

28. Use of a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus.

FOR "SUB A35"

29. Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71), murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) for the treatment of an inflammatory neurological disorder.

30. Use according to claim 29 wherein the inflammatory neurological disorder is multiple sclerosis.

31. Use according to claim 29 wherein the inflammatory neurological disorder is Parkinson's disease.

32. Use according to claim 29 wherein the inflammatory neurological disorder is Alzheimer's disease.

SUB
A36

33. Use of an antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of P16 (SEQ ID NO: 26), P32 (SEQ ID NO: 71),

murine S3 (SEQ ID NO: 73), human S3 (SEQ ID NO: 74), murine S7 (SEQ ID NO: 75), human S7 (SEQ ID NO: 76), murine V2 (SEQ ID NO: 77), human V2 (SEQ ID NO: 78) and human V3 (SEQ ID NO: 79) for the treatment of a disease selected from the group consisting of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus.